RT Journal Article
SR Electronic
T1 Type I, II, and III interferon signatures correspond to COVID-19 disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21253317
DO 10.1101/2021.03.10.21253317
A1 Kim, Myung-Ho
A1 Salloum, Shadi
A1 Wang, Jeffrey Y
A1 Wong, Lai Ping
A1 Regan, James
A1 Lefteri, Kristina
A1 Manickas-Hill, Zachary
A1 ,
A1 Li, Jonathan Z
A1 Sadreyev, Ruslan I
A1 Yu, Xu G
A1 Chung, Raymond T
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253317.abstract
AB We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged type I interferon responses with hyper-inflammation mediated by interferon regulatory factor 1. Type II interferon responses were compromised in ICU patients. Type III interferon responses were induced in the early phase of SARS-CoV-2 infection, even in convalescent patients. These results highlight the importance of type I and III interferon responses during the early phase of infection in controlling COVID-19 progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH U19 AI082630 and the MGH Research Scholars Program. The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness and the Ragon Institute of MGH, MIT and Harvard.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study conforms to the principles outlined in the Declaration of Helsinki and received approval by the Ethics Committees of the Massachusetts General Hospital, Boston, USA (approval number: 2020P000804) All participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable